FindTrial
Sign In

Incidence of Hospitalized Infection in Elderly Patients with Rheumatoid Arthritis on bDMARDs and tsDMARDs: A Healthcare Data-Based Cohort Study

Incidence of Hospitalized Infection in Elderly Patients with Rheumatoid Arthritis on bDMARDs and tsDMARDs: A Healthcare Data-Based Cohort Study - Incidence of Hospitalized Infection in Elderly Patients with Rheumatoid Arthritis on bDMARDs and tsDMARDs: A Healthcare Data-Based Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000037851
Enrollment
14000
Registered
2019-09-01
Start date
2019-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Sponsors

CHUGAI PHARMACEUTICAL CO.,LTD. MEDICAL SCIENCE DEPT
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with RA who started new bDMARDs and tsDMARDs after 2014

Exclusion criteria

Exclusion criteria: 1. Patients in hospital at baseline 2. Patients with other diseases indicated for the study therapy (behcet's disease, psoriasis, ankylosing spondylitis, kawasaki disease, crohn's disease, ulcerative colitis, juvenile idiopathic arthritis/adult still's disease, suppurative hidradenitis, castleman's disease, giant cell arteritis, takayasu's arteritis) at least once in the previous year

Design outcomes

Primary

MeasureTime frame
Number of infections requiring first hospitalized infection, morbidity (person-years), crude morbidity, crude hazard ratio of each bDMARDs and tsDMARDs to tocilizumab, adjusted hazard ratio, in elderly RA patients aged 75 years and older—

Countries

Japan

Contacts

Public ContactSatoshi Kondo

CHUGAI PHARMACEUTICAL CO.,LTD. MEDICAL SCIENCE DEPT

kondosts@chugai-pharm.co.jp03-3273-0866

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026